The blood-brain barrier in migraine treatment

Cephalalgia

Volumn 28, Issue 12, 2008, Pages 1245-1258

  Edvinsson, L ^a   Tfelt Hansen, P ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Animal headache models; Blood brain barrier; CGRP; Human headache model; Triptans

Indexed keywords

3 [2 (DIMETHYLAMINO)ETHYL] 5 (1,2,4 TRIAZOL 1 YL)INDOLE; ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; CANDESARTAN; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOMETRINE; ERGOTAMINE; GABAPENTIN; INDOMETACIN; KETOROLAC; LAMOTRIGINE; METHYSERGIDE; METOPROLOL; NAPROXEN; NARATRIPTAN; OLCEGEPANT; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; ZOLMITRIPTAN;

ALLODYNIA; ARTERIOGRAPHY; BLOOD BRAIN BARRIER; BLOOD VESSEL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DIFFUSION; DRUG EFFICACY; DRUG TRANSPORT; HUMAN; MIGRAINE; MIGRAINE WITH AURA; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEDATION; SIDE EFFECT; TRANSCYTOSIS; VIVID DREAM;

ANIMALS; BLOOD-BRAIN BARRIER; CALCITONIN GENE-RELATED PEPTIDE; DISEASE MODELS, ANIMAL; HUMANS; MIGRAINE DISORDERS; MODELS, NEUROLOGICAL; TRYPTAMINES; VASODILATOR AGENTS;

EID: 56549109172     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2008.01675.x     Document Type: Review

References (149)

1. Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, Ferrari MD. The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia 2006 26 : 1209 13.
2. Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev 2005 48 : 438 56.
3. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002 346 : 257 70.
4. Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides 2001 22 : 995 1007.
5. van Deurs B. Structural aspects of brain barrier, with special references to the permeability of the cerebral endothelium and choroid plexus. Int Rev Cytol 1980 65 : 117 91.
6. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004 10 : 1295 312.
7. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006 209 : 2304 11.
8. Smith QR, Rapoport SI. Cerebrovascular permeability coefficients to sodium, potassium, and chloride. J Neurochem 1986 46 : 1732 42.
9. Butt AM. Effect of inflammatory agents on electrical resistance across the blood-brain barrier in pial microvessels of anaesthetized rats. Brain Res 1995 696 : 145 50.
10. Nag S, Robertson DM, Dinsdale HB. Intracerebral arteriolar permeability to lanthanum. Am J Pathol 1982 107 : 336 41.
11. Cornford EM, Hyman S. Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx 2005 2 : 27 43.
12. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998 70 : 1781 92.
13. Yousif S, Marie-Claire C, Roux F, Scherrmann J-M, Declèves X. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 2007 1134 : 1 11.
14. Gjedde A, Christensen O. Estimates of Michaelis-Menten constants for the two membranes of the brain endothelium. J Cereb Blood Flow Metab 1984 4 : 241 9.
15. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998 273 : 23629 32.
16. Yee RE, Cheng DW, Huang SC, Namavari M, Satyamurthy N, Barrio JR. Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA. Biochem Pharmacol 2001 62 : 1409 15.
17. Paulson OB, Hertz MM, Bolwig TG, Lassen NA. Filtration and diffusion of water across the blood-brain barrier in man. Microvasc Res 1977 13 : 113 24.
18. Edvinsson L, Krause DN. Cerebral blood flow and metabolism. Philadelphia, PA : Lippincott Williams & Wilkins 2002.
19. Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 2003 31 : 861 9.
20. Millson DS, Tepper SJ, Rapoport AM. Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother 2000 1 : 391 404.
21. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007 320 : 331 43.
22. Sills GJ, Kwan P, Butler E, de Lange EC, van den Berg DJ, Brodie MJ. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002 3 : 427 32.
23. Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 2006 79 : 540 8.
24. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007 52 : 333 46.
25. Ward KW, Azzarano LM. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5- methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-i soquinolinyl) ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. J Pharmacol Exp Ther 2004 310 : 703 9.
26. Oldendorf WH. The blood-brain barrier. Exp Eye Res 1977 25 (Suppl. 177 90.
27. Burnstock G. Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J Anat 1999 194 (Pt 3 335 42.
28. Loesch A, Burnstock G. The endothelium: electron immunocytochemistry of vasoactive agents. In : Polak JM, ed. Modern visualisation of the endothelium. Amsterdam : Harwood Academic Publishers 1998 : 4 44.
29. Stenman E, Edvinsson L. Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. Stroke 2004 35 : 970 4.
30. Lansman JB. Endothelial mechanosensors. Going with the flow. Nature 1988 331 : 481 2.
31. + current in vascular endothelial cells. Nature 1988 331 : 168 70.
32. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994 117 (Pt 1 199 210.
33. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004 113 : 1447 55.
34. Fabricius M, Fuhr S, Bhatia R, Boutelle M, Hashemi P, Strong AJ, Lauritzen M. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain 2006 129 : 778 90.
35. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007 27 : 697 709.
36. Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA, Andersen AR, Karle A. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990 28 : 791 8.
37. Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez del Rio M, Lee EJ et al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998 43 : 25 31.
38. Sorensen AG, Buonanno FS, Gonzalez RG, Schwamm LH, Lev MH, Huang-Hellinger FR et al. Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging. Radiology 1996 199 : 391 401.
39. Dreier JP, Jurkat-Rott K, Petzold GC, Tomkins O, Klingebiel R, Kopp UA et al. Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology 2005 64 : 2145 7.
40. Jen JC, Wan J, Palos TP, Howard BD, Baloh RW. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 2005 65 : 529 34.
41. Cha YH, Millett D, Kane M, Jen J, Baloh R. Adult-onset hemiplegic migraine with cortical enhancement and oedema. Cephalalgia 2007 27 : 1166 70.
42. Jager HR, Giffin NJ, Goadsby PJ. Diffusion- and perfusion-weighted MR imaging in persistent migrainous visual disturbances. Cephalalgia 2005 25 : 323 32.
43. Hadjikhani N, Del Rio S, Wu M, Schwartz O, Bakker D, Fischl D et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001 98 : 4687 92.
44. Sanchez del Rio M, Bakker D, Wu O, Agosti R, Mitsikostas DD, Ostergaard L et al. Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 1999 19 : 701 7.
45. Edvinsson L, Nielsen KC, Owman C. Influence of initial tension and changes in sensitivity during amine-induced contractions of pial arteries in vitro. Arch Int Pharmacodyn Ther 1974 208 : 235 42.
46. Bryan RM Jr., You J, Golding EM, Marrelli SP. Endothelium-derived hyperpolarizing factor: a cousin to nitric oxide and prostacyclin. Anesthesiology 2005 102 : 1261 77.
47. Szok D, Hansen-Schwartz J, Edvinsson L. In depth pharmacological characterization of endothelin B receptors in the rat middle cerebral artery. Neurosci Lett 2001 314 : 69 72.
48. You J, Johnson TD, Childres WF, Bryan RM Jr. Endothelial-mediated dilations of rat middle cerebral arteries by ATP and ADP. Am J Physiol 1997 273 : H1472 7.
49. Tfelt-Hansen P, Nilsson E, Edvinsson L. Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat. J Headache Pain 2007 8 : 83 9.
50. Goadsby PJ, Gundlach AL. Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991 29 : 91 4.
51. Hansen-Schwartz J, Lovland Hoel N, Nilsson E, Tfelt-Hansen P, Edvinsson L. Endothelium-dependent relaxant responses to selective 5-HT(1B/1D) receptor agonists in the isolated middle cerebral artery of the rat. J Vasc Res 2003 40 : 561 6.
52. Hoel NL, Hansen-Schwartz J, Edvinsson L. Selective up-regulation of 5-HT(1B/1D) receptors during organ culture of cerebral arteries. Neuroreport 2001 12 : 1605 8.
53. Nilsson T, Longmore J, Shaw D, Olesen IJ, Edvinsson L. Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 1999 128 : 1133 40.
54. Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, a CGRP8-37, a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 2007 150 : 633 40.
55. Bergerot A, Storer RJ, Goadsby PJ. Dopamine inhibits trigeminovascular transmission in the rat. Ann Neurol 2007 61 : 251 62.
56. Hardebo JE, Edvinsson L, MacKenzie ET, Owman C. Histofluorescence study on monoamine entry into the brain before and after opening of the blood-brain barrier by various mechanisms. Acta Neuropathol 1979 47 : 145 50.
57. MacKenzie ET, McCulloch J, Harper AM. Influence of endogenous norepinephrine on cerebral blood flow and metabolism. Am J Physiol 1976 231 : 489 94.
58. MacKenzie ET, McCulloch J, O'Kean M, Pickard JD, Harper AM. Cerebral circulation and norepinephrine: relevance of the blood-brain barrier. Am J Physiol 1976 231 : 483 8.
59. McCulloch J, Harper AM. Cerebral circulation: effect of stimulation and blockade of dopamine receptors. Am J Physiol 1977 233 : H222 7.
60. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996 384 : 560 4.
61. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998 79 : 964 82.
62. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004 104 : 29 45.
63. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004 142 : 1171 81.
64. Fischer MJ, Koulchitsky S, Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 2005 25 : 5877 83.
65. Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005 58 : 698 705.
66. Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 2008 507 : 1277 99.
67. Edvinsson L, Jansen I, Kingman TA, McCulloch J. Cerebrovascular responses to capsaicin in vitro and in situ. Br J Pharmacol 1990 100 : 312 18.
68. Edvinsson L, Jansen Olesen I, Kingman TA, McCulloch J, Uddman R. Modification of vasoconstrictor responses in cerebral blood vessels by lesioning of the trigeminal nerve: possible involvement of CGRP. Cephalalgia 1995 15 : 373 83.
69. McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 1986 83 : 5731 5.
70. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993 33 : 48 56.
71. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994 117 (Pt 3 427 34.
72. Goadsby PJ, Edvinsson L. Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994 34 : 394 9.
73. Strassman AM, Levy D. Response properties of dural nociceptors in relation to headache. J Neurophysiol 2006 95 : 1298 306.
74. Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 2003 23 : 10988 97.
75. Strassman AM, Levy D. The anti-migraine agent sumatriptan induces a calcium-dependent discharge in meningeal sensory neurons. Neuroreport 2004 15 : 1409 12.
76. Burstein R, Jakubowski M, Levy D. Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. Pain 2005 115 : 21 8.
77. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 1996 67 : 355 9.
78. Hoskin KL, Goadsby PJ. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat. Exp Neurol 1998 150 : 45 51.
79. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993 109 : 788 92.
80. Cumberbatch MJ, Hill RG, Hargreaves RJ. Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 1998 18 : 659 63.
81. Goadsby PJ, Knight Y. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors. Br J Pharmacol 1997 122 : 918 22.
82. Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, Hargreaves RJ. Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol 1999 126 : 1478 86.
83. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 1997 328 : 37 40.
84. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci USA 2004 101 : 4274 9.
85. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007 130 : 166 76.
86. Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993 33 : 541 4.
87. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005 45 : 850 61.
88. Jakubowski M, Levy D, Kainz V, Zhang XC, Kosaras B, Burstein R. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience. 2007 148 : 573 83.
89. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004 350 : 1104 10.
90. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 2005 77 : 202 13.
91. Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 2004 143 : 697 704.
92. Hoskin KL, Bulmer DC, Goadsby PJ. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett 1999 266 : 173 6.
93. Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997 120 (Pt 12 2171 7.
94. Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res 2002 953 : 181 8.
95. Boers PM, Donaldson C, Zagami AS, Lambert GA. Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia 2004 24 : 99 109.
96. Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L, Olesen J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005 25 : 139 47.
97. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006 59 : 652 61.
98. Kangasniemi P, Andersen AR, Andersson PG, Gilhus NE, Hedman C, Hultgren M et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987 7 : 231 8.
99. Alemdar M, Akman O, Selekler HM, Komsuoglu SS, Ates N. Does metoprolol inhibit the cortical spreading depression? Acute effects of systematic metropol on CSD in rats. Cephalalgia 2007 27 : 1010 13.
100. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 2004 24 : 1049 56.
101. Tvedskov JF, Iversen HK, Olesen J. A double-blind study of SB-220453 (Tonerbasat) in the glyceryl trinitrate (GTN) model of migraine. Cephalalgia 2004 24 : 875 82.
102. Tvedskov JF, Thomsen LL, Iversen HK, Gibson A, Wiliams P, Olesen J. The prophylactic effect of valproate on glyceryl trinitrate induced migraine. Cephalalgia 2004 24 : 576 85.
103. Tvedskov JF, Thomsen LL, Iversen HK, Williams P, Gibson A, Jenkins K et al. The effect of propranolol on glyceryl trinitrate-induced headache and arterial response. Cephalalgia 2004 24 : 1076 87.
104. Smith MI, Read SJ, Chan WN, Thompson M, Hunter AJ, Upton N, Parsons AA. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 2000 20 : 546 53.
105. Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 1994 15 : 149 53.
106. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989 38 : 17 24.
107. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 1993 4 : 1027 30.
108. Thomsen LL, Iversen HK, Brinck TA, Olesen J. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia 1993 13 : 395 9 discussion 76
109. Afridi S, Kaube H, Goadsby PJ. Occipital activation in glyceryl trinitrate induced migraine with visual aura. J Neurol Neurosurg Psychiatry 2005 76 : 1158 60.
110. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 2004 110 : 675 80.
111. Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RS, Goadsby PJA. PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 2005 128 : 932 9.
112. You JP, Wang Q, Zhang W, Jansen-Olesen I, Paulson OB, Lassen NA, Edvinsson L. Hypercapnic vasodilatation in isolated rat basilar arteries is exerted via low pH and does not involve nitric oxide synthase stimulation or cyclic GMP production. Acta Physiol Scand 1994 152 : 391 7.
113. Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport 1995 6 : 1475 9.
114. Ottosson A, Jansen I, Edvinsson L. Characterization of histamine receptors in isolated human cerebral arteries. Br J Pharmacol 1988 94 : 901 7.
115. Lassen LH, Thomsen LL, Kruuse C, Iversen HK, Olesen J. Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine. Eur J Clin Pharmacol 1996 49 : 335 9.
116. Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia 2003 23 : 877 86.
117. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002 22 : 54 61.
118. Edvinsson L. Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci 1985 8 : 126 31.
119. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 2004 24 : 611 22.
120. Edvinsson L, Ekman R, Jansen I, Ottosson A, Uddman R. Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann Neurol 1987 21 : 431 7.
121. Edvinsson L, Gulbenkian S, Barroso CP, Cunha e Sa M, Polak JM, Mortensen A et al. Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides 1998 19 : 1213 25.
122. Jansen I, Uddman R, Hocherman M, Ekman R, Jensen K, Olesen J et al. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Ann Neurol 1986 20 : 496 501.
123. Olesen IJ, Gulbenkian S, Valenca A, Antunes JL, Wharton J, Polak JM, Edvinsson L. The peptidergic innervation of the human superficial temporal artery: immunohistochemistry, ultrastructure, and vasomotility. Peptides 1995 16 : 275 87.
124. Liew G, Wang JJ, Mitchell P. Migraine and coronary heart disease mortality: a prospective cohort study. Cephalalgia 2007 27 : 368 71.
125. Lassen LH, Jacobsen VB, Harderslev PA, Sperling B, Iversen H, Olesen J, Tfelt-Hansen P. Involvement of calcitonin gene-related peptide (CGRP) in migraine. Regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain 2008 9 : 151 7.
126. de Hoon JN, Smits P, Troost J, Struijker-Boudier HA, Van Bortel LM. Forearm vascular response to nitric oxide and calcitonin gene-related peptide: comparison between migraine patients and control subjects. Cephalalgia 2006 26 : 56 63.
127. Edvinsson M-L, Edvinsson L. Comparison of CGRP and NO responses in the human peripheral microcirculation of migraine and control subjects. Cephalalgia 2008 28 : 563 6.
128. Beattie DT, McNeil DK, Connor HE. The influence of neurokinins and calcitonin gene-related peptide on cerebral blood flow in anaesthetized guinea-pigs. Neuropeptides 1993 24 : 343 9.
129. Edvinsson L, Alm R, Shaw D, Rutledge RZ, Koblan KS, Longmore J, Kane SA. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 2002 434 : 49 53.
130. Troltzsch M, Denekas T, Messlinger K. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol 2007 562 : 103 10.
131. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 358 : 1668 75.
132. Goadsby PJ, Dodick DW, Almas M, Diener HC, Tfelt-Hansen P, Lipton RB, Parsons B. Treatment-emergent CNS symptoms following triptan therapy are part of the attack. Cephalalgia 2007 27 : 254 62.
133. Dahlof C, Hogenhuis L, Olesen J, Petit H, Ribbat J, Schoenen J et al. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 1998 5 : 469 77.
134. Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, Humphrey PP. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997 17 : 145 52.
135. Sullivan JT, Preston KL, Testa MP, Busch M, Jasinski DR. Psychoactivity and abuse potential of sumatriptan. Clin Pharmacol Ther 1992 52 : 635 42.
136. van der Post J, Schram MT, Schoemaker RC, Pieters MS, Fuseau E, Pereira A et al. CNS effects of sumatriptan and rizatriptan in healthy female volunteers. Cephalalgia 2002 22 : 271 81.
137. Olesen J, Hougard K, Hertz M. Isoproterenol and propranolol: ability to cross the blood-brain barrier and effects on cerebral circulation in man. Stroke 1978 9 : 344 9.
138. Tfelt-Hansen P, Rolan P. Beta-adrenoceptor blocking drugs in migraine prophylaxis. In : Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, eds. The headaches, 3rd edn. Philadelphia, PA : Lippincott Williams & Wilkins 2006 : 519 28.
139. Handforth A, Mai T, Treiman DM. Rising dose study of safety and tolerance of flunarizine. Eur J Clin Pharmacol 1995 49 : 91 4.
140. Pledger GW, Sackellares JC, Treiman DM, Pellock JM, Wright FS, Mikati M et al. Flunarizine for treatment of partial seizures: results of a concentration-controlled trial. Neurology 1994 44 : 1830 6.
141. Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ et al. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004 251 : 943 50.
142. Silberstein SD, Tfelt-Hansen P. Antiepileptic drugs in migraine prophylaxis. In : Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA : Lippincott Williams & Wilkins 2006 : 545 51.
143. Jansen I, Tfelt-Hansen P, Edvinsson L. Comparison of the calcium entry blockers nimodipine and flunarizine on human cerebral and temporal arteries: role in cerebrovascular disorders. Eur J Clin Pharmacol 1991 40 : 7 15.
144. Toda N, Tfelt-Hansen P. Calcium antagonists in migraine prophylaxis. In : Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA : Lippincott Williams & Wilkins 2006 : 539 44.
145. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992 576 : 203 7.
146. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001 21 : 7724 32.
147. Back T, Kohno K, Hossmann KA. Cortical negative DC deflections following middle cerebral artery occlusion and KCl-induced spreading depression: effect on blood flow, tissue oxygenation, and electroencephalogram. J Cereb Blood Flow Metab 1994 14 : 12 19.
148. Nedergaard M, Hansen AJ. Characterization of cortical depolarizations evoked in focal cerebral ischemia. J Cereb Blood Flow Metab 1993 13 : 568 74.
149. Kruit MC, van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, Launer LJ. Migraine as a risk factor for subclinical brain lesions. JAMA 2004 291 : 427 34.